Form 4: Spyre Therapeutics Directors Granted Stock Options, Aligning Interests with Long-Term Growth

Key directors Peter Harwin and Tomas Kiselak, associated with Fairmount Funds, were granted stock options to purchase 50,000 shares of Spyre Therapeutics common stock, vesting over 12 months.

Summary

• Peter Harwin, a director of Spyre Therapeutics, Inc., was granted stock options to purchase 25,000 shares of the Issuer's common stock.
• Tomas Kiselak, also a director of Spyre Therapeutics, Inc., was granted stock options to purchase an additional 25,000 shares of the Issuer's common stock.
• Both sets of stock options have an exercise price of $15.55 per share.
• The options will vest and become exercisable in 12 equal monthly installments following May 29, 2025, subject to the continuous service of Mr. Harwin and Mr. Kiselak, respectively.
• The expiration date for both stock option grants is May 29, 2035.
• Mr. Harwin and Mr. Kiselak hold these options for the benefit of investment vehicles managed by Fairmount Funds Management LLC (the "Adviser") and are obligated to turn over any net cash or stock received to the Adviser for the benefit of such Fairmount Fund, disclaiming beneficial ownership except for their pecuniary interest.
• Fairmount Funds Management LLC and Fairmount Healthcare Fund II L.P. are deemed directors by deputization due to Peter Harwin and Tomas Kiselak serving on the board and being Managing Members of the Adviser.

Sentiment

Score: 7

Explanation: The granting of stock options to key directors is generally viewed positively as it aligns their long-term interests with the company's performance and shareholder value, encouraging retention and strategic focus. While not a direct operational or financial announcement, it reflects standard governance practices aimed at incentivizing leadership.

Positives

• The granting of stock options to directors aligns their long-term financial interests with the performance of Spyre Therapeutics and its shareholders.
• The 12-month vesting schedule encourages continued service and commitment from key directors, fostering stability and strategic continuity.
• The options provide an incentive for directors to work towards increasing the company's stock price above the exercise price of $15.55.

Negatives

• The options represent potential future dilution for existing shareholders if and when they are exercised.
• There is no immediate cash investment by the directors, as these are grants rather than purchases of shares.

Risks

• The vesting of the stock options is contingent upon the continuous service of Peter Harwin and Tomas Kiselak with the Issuer; if their service ceases, unvested options may be forfeited.
• The value of the stock options is dependent on the future market price of Spyre Therapeutics' common stock exceeding the exercise price of $15.55; if the stock price remains below this level, the options may not be profitable to exercise.

Future Outlook

The document primarily details an insider equity grant and does not provide forward-looking statements regarding the company's financial performance, operational guidance, or strategic outlook beyond the vesting schedule of the granted options.

Management Comments

• "Under Mr. Harwin's arrangement with Fairmount Funds Management LLC (the 'Adviser'), Mr. Harwin holds the option for one or more investment vehicles managed by the Adviser (each, a 'Fairmount Fund'). Mr. Harwin is obligated to turn over to the Adviser any net cash or stock received from the option for the benefit of such Fairmount Fund. Mr. Harwin therefore disclaims beneficial ownership of the option and underlying common stock, except to the extent of his pecuniary interest therein."
• "Under Mr. Kiselak's arrangement with Fairmount Funds Management LLC (the 'Adviser'), Mr. Kiselak holds the option for one or more investment vehicles managed by the Adviser (each, a 'Fairmount Fund'). Mr. Kiselak is obligated to turn over to the Adviser any net cash or stock received from the option for the benefit of such Fairmount Fund. Mr. Kiselak therefore disclaims beneficial ownership of the option and underlying common stock, except to the extent of his pecuniary interest therein."
• "The Adviser and Fairmount Healthcare Fund II L.P. may each be deemed a director by deputization of Issuer by virtue of the fact that each of Peter Harwin and Tomas Kiselak serve on the board of directors of the Issuer and are also each a Managing Member of the Adviser."

Industry Context

This Form 4 filing is a routine disclosure of insider equity compensation. It does not provide information on broader industry trends, competitive landscape, or market position, as its scope is limited to changes in beneficial ownership of securities by company insiders.

Management Changes

Corporate Governance

Related Party Transactions

• The stock options were granted to Peter Harwin and Tomas Kiselak, who are directors of Spyre Therapeutics and also Managing Members of Fairmount Funds Management LLC. Fairmount Funds Management LLC and Fairmount Healthcare Fund II L.P. are explicitly stated as being deemed directors by deputization, indicating a related party relationship in the context of this compensation.

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also benefit from enhanced alignment of director incentives with long-term company performance and shareholder value.
• Management/Directors: Peter Harwin and Tomas Kiselak receive equity-based compensation that incentivizes their continued service and contribution to the company's growth.

Next Steps

• Continued service of Peter Harwin and Tomas Kiselak to ensure the vesting of their respective stock options.
• Potential future exercise of the stock options by the reporting persons if Spyre Therapeutics' common stock price exceeds the exercise price of $15.55.

Key Dates

Recommendation

Keywords

Spyre Therapeutics, SYRE, Stock Options, Insider Transaction, Form 4, Director Compensation, Equity Grant, Fairmount Funds Management, Peter Harwin, Tomas Kiselak, Beneficial Ownership